

## Special Issue

# Advances in Triple-Negative Breast Cancer

### Message from the Guest Editor

Among all breast cancers (BCs), the triple-negative (TN) subtype drives a grim outcome to patients due to its aggressive behavior and the lack of druggable identified targets. In recent years, checkpoint-inhibitor-based immunotherapy has emerged as a new therapy in this biologic subtype that has improved patients' survival, based on tumor immune signatures, tumor mutational burden, tumor-infiltrating lymphocytes, the PD-L1/PD-1 axis, and other factors related to individual patients. On the other hand, the incorporation of PARP inhibitors, antibody drug conjugates, BC vaccines, and active as well as adoptive cell immunotherapy aims to improve the landscape to treat this population of TNBC patients, both in monotherapy and in combination. All of the new therapeutic strategies have important roles in this scenario, tackling this disease in different ways, which permits the de-escalation of conventional chemotherapy. This Special Issue, entitled "Advances in Triple-Negative Breast Cancer", aims to approach novel biomarkers and therapeutic strategies to improve patients' outcomes and quality of life.

### Guest Editor

Dr. Marta Santisteban

Medical Oncology, Breast Cancer Unit, Clínica Universidad de Navarra, 31008 Pamplona, Spain

### Deadline for manuscript submissions

closed (10 April 2024)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/164415](https://mdpi.com/si/164415)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)